Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases.
Hofbauer
L C
LC
Division of Gastroenterology and Endocrinology, Zentrum für Innere Medizin, Philipps University, Marburg, Germany. hofbauer@post.med.uni-marburg.de
Heufelder
A E
AE
D000818:Animals; D001851:Bone Diseases, Metabolic / Q000188:drug therapy* / Q000503:physiopathology*; D006023:Glycoproteins / Q000502:physiology* / Q000627:therapeutic use*; D006801:Humans; D008024:Ligands; D016328:NF-kappa B / Q000235:genetics / Q000502:physiology*; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; D011994:Recombinant Proteins
D006023:Glycoproteins; D008024:Ligands; D016328:NF-kappa B; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; D011994:Recombinant Proteins; C506030:TNFRSF11B protein, human